Skip to main content

Remote Job Finders (RJF)

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the overall survival bar.
Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss
Scroll to top